You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
One project aims to collect patients' genomic and molecular information in a database, and another aims to tailor treatments based on patients' molecular profiles.
The Phase 0 trial will assess whether infigratinib can cross the blood-brain barrier to penetrate recurrent high-grade gliomas harboring FGFR genetic alterations.
Use of the drug resulted in an encouraging response when an infant patient received it off-label in a first-line setting.
Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
One cohort will involve NSCLC patients with MET exon 14 skipping mutations, while two other cohorts will enroll patients with solid tumors with MET amplifications and fusions.
The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.
The first-in-class VT1021 would treat patients with various cancers whose tumors have high CD36 expression by reprogramming the tumor immune microenvironment.
The trial will evaluate the effects of the single agent ONC201 in patients who have recurrent high-grade gliomas with low EGFR expression.
The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.